Publication:
Sorafenib-Induced Pancreatitis

Simple item page
dc.authorscopusid6603155277
dc.authorscopusid56641035600
dc.authorscopusid24066287600
dc.authorscopusid56604790800
dc.authorscopusid37080733400
dc.authorscopusid6507627491
dc.authorscopusid6603629209
dc.contributor.authorAyyildiz, T.
dc.contributor.authorAydın, T.
dc.contributor.authorEminler, A.T.
dc.contributor.authorYıldırım, C.
dc.contributor.authorIrak, K.
dc.contributor.authorKıyıcı, M.
dc.contributor.authorGürel, S.
dc.date.accessioned2020-06-21T09:43:11Z
dc.date.available2020-06-21T09:43:11Z
dc.date.issued2015
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Ayyildiz] Talat, Department of Gastroenterology, Ondokuz Mayis Üniversitesi, Samsun, Turkey; [Aydın] Taner, Department of Internal Medicine, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Eminler] Ahmet Tarik, Department of Gastroenterology, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Yıldırım] Çınar, Department of Gastroenterology, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Irak] Kader, Department of Gastroenterology, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Kıyıcı] Murat, Department of Gastroenterology, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Gürel] Selim, Department of Gastroenterology, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Nak] Selim Giray, Department of Gastroenterology, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Gülten] Macit It, Department of Gastroenterology, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkey; [Dolar] Enver, Department of Gastroenterology, Bursa Uludağ Üniversitesi, Bursa, Bursa, Turkeyen_US
dc.description.abstractSorafenib is an inhibitor of multikinase proteins which is used for metastatic renal cell carcinoma and advanced stage hepatocellular carcinoma. Its side effects include serum amylase and lipase elevations anticipated to occur within first weeks of treatment but clinically and radiologically evident acute pancreatitis develops rarely. Five cases of acute pancreatitis have been reported in literature until date. The case we described here is the sixth case of clinically diagnosed acute pancreatitis. © 2015 OMU.en_US
dc.identifier.doi10.5835/jecm.omu.32.03.008
dc.identifier.endpage135en_US
dc.identifier.issn1309-4483
dc.identifier.issn1309-5129
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85006651454
dc.identifier.scopusqualityQ4
dc.identifier.startpage133en_US
dc.identifier.urihttps://doi.org/10.5835/jecm.omu.32.03.008
dc.identifier.volume32en_US
dc.language.isoenen_US
dc.publisherOndokuz Mayis Universitesi Samsun 55139en_US
dc.relation.ispartofJournal of Experimental and Clinical Medicine (Turkey)en_US
dc.relation.journalJournal of Experimental and Clinical Medicine (Turkey)en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHepatocellular Carcinomaen_US
dc.subjectPancreatitisen_US
dc.subjectSorafeniben_US
dc.subjectTyrosine Kinase Inhibitoren_US
dc.titleSorafenib-Induced Pancreatitisen_US
dc.typeArticleen_US
dspace.entity.typePublication

Files

Collections

Scopus İndeksli Yayınlar Koleksiyonu